Chemed (CHE) Set to Release Quarterly Earnings on Tuesday

Key Points

• Chemed is expected to report Q3 2026 results after Tuesday’s market close, with analysts forecasting $6.39 in earnings per share and $685.04 million in revenue. The company’s full-year EPS guidance is 25.00–25.75.
• In the prior quarter, Chemed exceeded expectations with $6.06 EPS and $673.25 million in revenue, while revenue grew 8.8% year over year.
• Chemed raised its quarterly dividend to $0.70 per share, but analyst sentiment remains mixed: the stock has an average “Hold” rating and a consensus price target of $554.60.

Chemed (NYSE:CHE - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of $6.39 per share and revenue of $685.04 million for the quarter. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Investors may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 10:00 AM ET.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 EPS for the quarter, beating analysts' consensus estimates of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. During the same period in the previous year, the business posted $4.27 earnings per share. Chemed's quarterly revenue was up 8.8% on a year-over-year basis. On average, analysts expect Chemed to post $23.55 EPS for the current fiscal year and $25.17 EPS for the next fiscal year.

Chemed Price Performance

Shares of NYSE:CHE opened at $508.20 on Tuesday. The company has a 50-day simple moving average of $516.74 and a 200-day simple moving average of $472.72. Chemed has a one year low of $365.20 and a one year high of $557.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of 23.88, a PEG ratio of 2.06 and a beta of 0.51.

Chemed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were issued a dividend of $0.70 per share. This is an increase from Chemed's previous quarterly dividend of $0.60. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 17th. Chemed's dividend payout ratio is 14.06%.

Insiders Place Their Bets

In other Chemed news, EVP Spencer Lee sold 1,000 shares of the company's stock in a transaction on Friday, August 21st. The shares were sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the transaction, the executive vice president owned 13,912 shares in the company, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin McNamara sold 2,000 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the sale, the chief executive officer owned 70,418 shares of the company's stock, valued at $37,991,215.18. This trade represents a 2.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 9,190 shares of company stock worth $4,833,160. 3.33% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CHE has been the topic of several recent research reports. Wall Street Zen upgraded Chemed from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 10th. UBS Group started coverage on Chemed in a research note on Friday, September 25th. They set a "buy" rating and a $650.00 price objective for the company. Bank of America reaffirmed a "neutral" rating on shares of Chemed in a research report on Wednesday, July 29th. Weiss Ratings upgraded Chemed from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Finally, Oppenheimer upped their price target on Chemed from $500.00 to $590.00 and gave the stock an "outperform" rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $554.60.

Chemed Company Profile

Chemed Corporation NYSE: CHE is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients' homes, hospice inpatient units, hospitals, nursing facilities and other care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.